<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36978144</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>The influence of intrathecal injection of methotrexate and dexamethasone on neuropsychiatric systemic lupus erythematosus (NPSLE): a retrospective cohort study of 386 patients with NPSLE.</ArticleTitle><Pagination><StartPage>50</StartPage><MedlinePgn>50</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">50</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-023-03030-w</ELocationID><Abstract><AbstractText Label="BACKGROUND">Neuropsychiatric involvement is one of the major concerns in systemic lupus erythematosus (SLE). The therapeutic effect of intrathecal treatment of methotrexate and dexamethasone has been investigated in some exploratory studies, but its influence on the long-term prognosis of neuropsychiatric SLE (NPSLE) remains unknown.</AbstractText><AbstractText Label="METHODS">This was a propensity score-matched retrospective study. Outcomes at discharge and time free from NPSLE relapse or death were evaluated by multivariate logistic regression, survival analysis, and Cox regression as appropriate.</AbstractText><AbstractText Label="RESULTS">Among 386 hospitalized patients with NPSLE, the median [IQR] age was 30.0&#x2009;[23.0-40.0] years, and 342 patients (88.4%) were female. Of those, 194 patients received intrathecal treatment. Patients in the intrathecal treatment group had higher Systemic Lupus Erythematosus Disease Activity Index 2000 scores (median 17 vs. 14&#xa0;points, IQR 12-22 vs. 10-19&#xa0;points, P&#x2009;&lt;0&#x2009;.001) and were more likely to receive methylprednisolone pulse therapy (71.6% vs. 49.5%, P &lt; 0.001) than those who did not receive intrathecal therapy. Intrathecal treatment was associated with a higher probability of survival and being free from NPSLE relapse than control treatment among the 386 unmatched patients (P =0.042 by log-rank test) and within 147 propensity score-matched pairs (P =0.032 by log-rank test). In the subgroup of NPSLE patients with increased levels of protein in cerebrospinal fluid, intrathecal treatment had a positive influence on their prognosis (P &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS">Intrathecal treatment of methotrexate and dexamethasone was associated with a more favorable prognosis of NPSLE and may serve as a valuable additional therapy for NPSLE patients, especially for those with elevated levels of protein in cerebrospinal fluid.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Yuxue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Boyuan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Minmin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Zhongshan Boai Hospital Affiliated to Southern Medical University, Zhongshan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Di</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yunjiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiaxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Linyi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Jingwen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengtao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. xiaofeng.zeng@cstar.org.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. wangli2221@sina.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. zhangwen91@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Arthritis Res Ther. 2023 Apr 29;25(1):71</RefSource><PMID Version="1">37120566</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020945" MajorTopicYN="Y">Lupus Vasculitis, Central Nervous System</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007278" MajorTopicYN="N">Injections, Spinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Neurologic manifestations</Keyword><Keyword MajorTopicYN="N">Systemic</Keyword><Keyword MajorTopicYN="N">Therapy</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36978144</ArticleId><ArticleId IdType="pmc">PMC10045150</ArticleId><ArticleId IdType="doi">10.1186/s13075-023-03030-w</ArticleId><ArticleId IdType="pii">10.1186/s13075-023-03030-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahn GY, Kim D, Won S, et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus. 2018;27(8):1338&#x2013;1347. doi: 10.1177/0961203318772021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318772021</ArticleId><ArticleId IdType="pubmed">29688144</ArticleId></ArticleIdList></Reference><Reference><Citation>Unterman A, Nolte JE, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41(1):1&#x2013;11. doi: 10.1016/j.semarthrit.2010.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2010.08.001</ArticleId><ArticleId IdType="pubmed">20965549</ArticleId></ArticleIdList></Reference><Reference><Citation>The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis and rheumatism. 1999;42(4):599-608.&#xa0;10.1002/1529-0131(199904)42:43.0.CO;2-F.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly, J. Diagnosis and management of neuropsychiatric SLE.&#xa0;Nat Rev Rheumatol&#xa0;10, 338&#x2013;347 (2014). 10.1038/nrrheum.2014.15.</Citation><ArticleIdList><ArticleId IdType="pubmed">24514913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the 5. EULAR standing committee for clinical affairs. Ann&#xa0; Rheum Dis. 2010;69(12):2074&#x2013;2082. doi: 10.1136/ard.2010.130476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.130476</ArticleId><ArticleId IdType="pubmed">20724309</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Valesini G, Priori R, Francia A, et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol. 1994;16(2&#x2013;3):313&#x2013;321. doi: 10.1007/BF00197524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00197524</ArticleId><ArticleId IdType="pubmed">7716711</ArticleId></ArticleIdList></Reference><Reference><Citation>Xuan Z, Yi D, Fu-Lin T, Fen-Chun Z. Central nervous system involvement in systemic lupus erythematosus in a hospital-based study of 171 cases: the possible therapeutic role of intrathecal therapy. J Clinl Rheumatol. 1999;5(6):314&#x2013;319. doi: 10.1097/00124743-199912000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00124743-199912000-00003</ArticleId><ArticleId IdType="pubmed">19078422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou HQ, Zhang FC, Tian XP, et al. Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus. 2008;17(2):93&#x2013;99. doi: 10.1177/0961203307085671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307085671</ArticleId><ArticleId IdType="pubmed">18250131</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the systemic lupus erythematosus. Am J Med. 1995;98:32&#x2013;41. doi: 10.1016/S0002-9343(99)80078-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(99)80078-3</ArticleId><ArticleId IdType="pubmed">7825616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhao Y, Zhang J, et al. Impact analysis of autoantibody level and NR2 antibody level in neuropsychiatric SLE treated by methylprednisolone combined with MTX and DXM intrathecal injection. Cell Biochem Biophys. 2014;70(2):1005&#x2013;1009. doi: 10.1007/s12013-014-0010-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12013-014-0010-9</ArticleId><ArticleId IdType="pubmed">24845150</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetto U, Head SJ, Angelini GD, Blackstone EH. Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg. 2018;53(6):1112&#x2013;1117. doi: 10.1093/ejcts/ezy167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezy167</ArticleId><ArticleId IdType="pubmed">29684154</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and rheumatism. 2012;64(8):2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache classification committee of the International Headache Society. Cephalalgia1988;8(suppl 7):1&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">3048700</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Rahman A, Allen E. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44(7):902&#x2013;906. doi: 10.1093/rheumatology/keh624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh624</ArticleId><ArticleId IdType="pubmed">15814577</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortoluzzi A, Scir&#xe8; CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford) 2015;54(5):891&#x2013;898. doi: 10.1093/rheumatology/keu384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu384</ArticleId><ArticleId IdType="pubmed">25339643</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill S, Cervera R. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2010;24(6):841&#x2013;855. doi: 10.1016/j.berh.2010.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2010.10.006</ArticleId><ArticleId IdType="pubmed">21665130</ArticleId></ArticleIdList></Reference><Reference><Citation>Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 1994;37(9):1311&#x2013;1320. doi: 10.1002/art.1780370907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780370907</ArticleId><ArticleId IdType="pubmed">7945494</ArticleId></ArticleIdList></Reference><Reference><Citation>Barile-Fabris L, Ariza-Andraca R, Olgu&#xed;n-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheumatic Dis. 2005;64(4):620&#x2013;625. doi: 10.1136/ard.2004.025528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.025528</ArticleId><ArticleId IdType="pmc">PMC1755456</ArticleId><ArticleId IdType="pubmed">15769918</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheumatic Dis. 2007;66(4):470&#x2013;475. doi: 10.1136/ard.2006.057885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.057885</ArticleId><ArticleId IdType="pmc">PMC1856059</ArticleId><ArticleId IdType="pubmed">17107983</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Nebro A, de la Fuente JL, Carre&#xf1;o L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2112;21(10):1063-1076. 10.1177/0961203312446627</Citation><ArticleIdList><ArticleId IdType="pubmed">22786985</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142&#x2013;150. doi: 10.1212/WNL.0000000000000570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000570</ArticleId><ArticleId IdType="pmc">PMC4117174</ArticleId><ArticleId IdType="pubmed">24920861</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Therapeutic Apheresis Dialysis. 2003;7(2):173&#x2013;182. doi: 10.1046/j.1526-0968.2003.00032.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1526-0968.2003.00032.x</ArticleId><ArticleId IdType="pubmed">12918940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolucci P, Br&#xe9;chignac S, Cohen P, Le Guern V, Guillevin L. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus. 2007;16(10):817&#x2013;822. doi: 10.1177/0961203307081840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307081840</ArticleId><ArticleId IdType="pubmed">17895305</ArticleId></ArticleIdList></Reference><Reference><Citation>Govoni M, Hanly JG. The management of neuropsychiatric lupus in the 21st century: still so many unmet needs? Rheumatology (Oxford) 2020;59(Suppl5):v52&#x2013;v62. doi: 10.1093/rheumatology/keaa404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa404</ArticleId><ArticleId IdType="pmc">PMC7719041</ArticleId><ArticleId IdType="pubmed">33280014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>